Arexvy

News

GSK gets EU okay for RSV shot in younger age group

GSK has claimed a new approval for its respiratory syncytial virus (RSV) vaccine Arexvy, currently locked in a battle for market share with rival shots from Pfizer and Moderna, that could l

News

Moderna gets FDA okay for RSV vaccine mResvia

Moderna has secured FDA approval for its respiratory syncytial virus (RSV) vaccine, giving it a chance to generate revenue from a second product as sales of its Spikevax C

News

GSK on top in RSV jab rollout, but is Pfizer closing the gap...

GSK and Pfizer’s full-year financial results show that the former is currently winning the battle for take-up of their rival respiratory syncytial virus (RSV) vaccines, al

News

GSK grabs early lead in RSV vaccine race with Pfizer

It is still very early days, but GSK’s respiratory syncytial virus (RSV) Arexvy seems to have flown out of the traps more quickly than Pfizer’s rival shot Abrysvo in the f

News

GSK targets younger age group with RSV jab Arexvy

GSK has reported new clinical data pointing to a benefit with its respiratory syncytial virus (RSV) vaccine Arexvy when used to treat a younger age group than the over-60s

News

GSK to lean on Zhifei for Shingrix and maybe Arexvy in China

GSK is enlisting the aid of China’s Chongqing Zhifei Biological Products (Zhifei) to drive sales of its most important vaccine, Shingrix, in China over the next few years,

GSK gets EU okay for RSV shot in younger age group

Moderna gets FDA okay for RSV vaccine mResvia

GSK on top in RSV jab rollout, but is Pfizer closing the gap...

GSK grabs early lead in RSV vaccine race with Pfizer

GSK targets younger age group with RSV jab Arexvy

GSK to lean on Zhifei for Shingrix and maybe Arexvy in China

Allogeneic cell therapy isn’t dead, with Brian Culley

How to meet your physicians where they are online

Arexvy

Editor's Picks